by fibralign | Oct 16, 2025 | Uncategorized
Fibralign Corp. and leading physicians presented an update on clinical findings and case studies during the 30th World Congress of the International Society of Lymphology (ISL), which was held 15-19 October 2025 in Antalya, Turkey. As part of this session, Dr. Corrado...
by fibralign | Jul 31, 2025 | Uncategorized
Fibralign Corp. and its South Korean distributor Healing Solutions, LTD announced today that Good Moonwha Hospital completed its 100th BioBridge case in the surgical treatment of lymphedema. Good Moonhwa is the first medical center in Asia and second worldwide to...
by fibralign | Jun 15, 2025 | Uncategorized
Terumo Corporation announced that the first clinical trial conducted in Japan for evaluation the BioBridge® Collagen Matrix in the surgical treatment of lymphedema has reached its endpoint. Terumo is managing and funding clinical studies in Japan which are being used...
by Alan McCann | Jan 20, 2022 | Uncategorized
Fibralign hosted the Lymphedema Summit on January 23, 2022, an international research seminar focused on “Advancements in Lymphedema Surgical Treatment.” This special event featured a gathering of the leading surgeons and researchers in this field and took...
by fibralign | Jun 10, 2021 | Uncategorized
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ — The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...
by fibralign | Apr 15, 2021 | Uncategorized
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment April 14, 2021 – The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge™, a randomized clinical study to evaluate a...
